Source comparison
Stacking BPC-157 + MK-677: Detailed Comparison
BPC-157 Stabilises nitric oxide signalling; upregulates VEGF and fibroblast growth factor at injury sites 200–500mcg daily (subcutaneous injection) ~4 hours (requires daily dosing) Accelerates angiogenesis and early-stage tissue repair; reduces inflammation at
This comparison does not assign a generated winner or score.
- BPC-157
- Stabilises nitric oxide signalling; upregulates VEGF and fibroblast growth factor at injury sites
- 200–500mcg daily (subcutaneous injection)
- ~4 hours (requires daily dosing)
- Accelerates angiogenesis and early-stage tissue repair; reduces inflammation at injury sites
- Effects plateau after 4–6 weeks in monotherapy; requires injection near injury site for maximum local effect
- Best for acute injury phases (weeks 0–8); synergy with systemic anabolic support extends utility
- MK-677
- Ghrelin receptor agonist; stimulates pulsatile GH release and sustained IGF-1 elevation
- 10–25mg daily (oral)
- ~24 hours
- Maintains elevated systemic IGF-1 for collagen synthesis and protein anabolism throughout healing
- Does not localise repair signalling; water retention and appetite increase at higher doses
- Best for sustaining the anabolic environment during weeks 4–16 of healing; complements localised repair peptides
- Combined Stack
- Synergistic: local growth factor upregulation (BPC-157) + systemic IGF-1 maintenance (MK-677)
- 250–350mcg BPC-157 + 12.5–20mg MK-677 daily
- Complementary pharmacokinetics
- Extends the functional healing window beyond 8 weeks; supports collagen remodelling and tensile strength gains
- Requires adherence to both injection and oral protocols; cost and complexity higher than monotherapy
- Most effective for injuries requiring structural remodelling (tendons, ligaments, post-surgical repair) rather than superficial tissue healing